Evaluation of cost savings to a state medicaid program following a sertraline tablet-splitting program

Journal of the American Pharmacists Association

Volumn 43, Issue 4, 2003, Pages 497-502

  Vuchetich, Phillip J ^a   Garis, Robert I ^a   Jorgensen, Allison M D ^b  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b Nebraska Pharmacists Association   (United States)

Author keywords

Citalopram; Drug costs; Fluoxetine; Fluvoxamine; Insurance claim review; Paroxetine; Pharmaceutical economics; Prescription fees; Retrospective studies; Sertraline

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; COMPARATIVE STUDY; COST CONTROL; DEPRESSION; DRUG COST; ECONOMICS; FEE; HUMAN; INFORMATION PROCESSING; MEDICAID; METHODOLOGY; PRESCRIPTION; RETROSPECTIVE STUDY; TABLET; UNITED STATES;

COST CONTROL; COST SAVINGS; DATA COLLECTION; DEPRESSIVE DISORDER; DRUG COSTS; HUMANS; MEDICAID; NEBRASKA; PRESCRIPTION FEES; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TABLETS;

EID: 0642335875     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434503322226248     Document Type: Article

References (17)

1. Bult J, Schiff G, Wisniewski M. Sertraline tablet splitting program. Hosp Pharm. 1999;34:996-9.
2. Panzarino PJ Jr., Xuan J. Economic evaluation of major selective serotonin reuptake inhibitors in a managed care population. Manage Care Interface. 2001;14:59-65.
3. Carr-Lopez SM, Mallett MS, Morse T. The tablet splitter: barrier to compliance or cost-saving instrument? Am J Health Syst Pharm. 1995;52:2707-8.
4. McDevitt JT, Gurst AH, Chen Y. Accuracy of tablet splitting. Pharmacotherapy. 1998;18:193-7.
5. Rosenberg JM, Joseph NP, Plakogiannis F. Weight variability of pharmacist-dispensed split tablets. J Am Pharm Assoc. 2002;42:200-5.
6. Teng J, Song CK, Williams RL, Polli JE. Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc. 2002;42:195-9.
7. Valdez C, Grier D. Determining the most economical SSRI for a Medicare risk contract. Am J Health Syst Pharm. 1999;56:23-4.
8. Nurnberg HG, Hensley PL, Thompson PM, Paine SS. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors. Psychiatr Serv. 1999;50:1351-3.
9. Fawell NG, Cookson TL, Scranton SS. Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance. Am J Health Syst Pharm. 1999;56:2542-5.
10. Rindone JP, Arriola G. Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost. Clin Ther. 1998;20:340-6.
11. Erdmann C. Drug costs. Double your measure. Hosp Health Netw. 1999;73:16, 18, 20.
12. Sedrati M, Arnaud P, Fontan JE, Brion F. Splitting tablets in half. Am J Hosp Pharm. 1994;51:548, 550.
13. U.S. Pharmacopeial Convention. Uniformity of dosage units. USP25-NF20: U.S. Pharmacopeia and National Formulary. Rockville, Md: United States Pharmacopeial Convention, Inc; 2002. 2082-4.
14. U.S. Pharmacopeial Convention. Pharmacy compounding. USP25-NF20: U.S. Pharmacopeia and National Formulary. Rockville, Md: United States Pharmacopeial Convention, Inc; 2002. 2053-7.
15. Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manage Care. 1999;5:597-606.
16. Price-Chek PC database. San Bruno, Calif: FirstDataBank; 2002.
17. Siegel S, Castellan NJ. The case of one sample, two measures or paired replicates. In: Nonparametric Statistics for the Behavioral Sciences. 2nd ed. New York, NY: McGraw-Hill, Inc; 1988:73-101.